Business Wire (Tue, 4:00PM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
802 people get ALNY articles and Market Currents by email alert.
Get email alerts on ALNY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (Wed, 4:00PM)
-
Business Wire (May 8, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 23, 2013)
-
-
-
-
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
-
Business Wire (Feb 7, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alnylam and Takeda Form Alliance In RNAiEben Tessari • Tue, May 27, 2008 -
-
-
-
-
-
-
-
-
-
-
7 Biotech Stocks Trading At Steep Discount To Target PriceKapitall • Thu, Nov 15, 2012 -
Casey Analyst Forecasts Explosive Biotech GrowthLife Sciences Report • Thu, Oct 11, 2012
-
-
-
-
-
China Biotech In Review: Deals, Trials And RegulationsChinaBio Today • Sun, Jul 15, 2012
-
-
-
-
-
Alnylam's CEO Discusses Q3 2012 Results - Earnings Call TranscriptMon, Nov 5, 2012 • 1 Comment
-
Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call TranscriptThu, Aug 5, 2010 • 2 Comments
-
Alnylam Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptWed, May 5, 2010
-
Alnylam Pharmaceuticals, Inc. Q4 2008 Earnings Call TranscriptWed, Feb 25, 2009
-
Business Wire (Tue, 4:00PM)
-
Business Wire (Wed, 4:00PM)
-
Business Wire (May 8, 2013)
-
Business Wire (May 6, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Apr 23, 2013)
-
at CNBC.com (Apr 3, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 26, 2013)
-
at CNBC.com (Feb 22, 2013)
-
Business Wire (Feb 7, 2013)
-
Business Wire (Feb 5, 2013)
-
Business Wire (Jan 31, 2013)
-
Business Wire (Jan 16, 2013)
-
Business Wire (Jan 15, 2013)
-
Business Wire (Jan 14, 2013)
ALNY vs. ETF Alternatives
Company Description
Currently, there's no company description for ALNY.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, November 5, 2012, 12:10 AM Notable earnings after Monday’s close: ALNY, CF, CLNE, CTRP, CVI, DEPO, ED, ENOC, EOG, ESRX, FIS, FNF, JIVE, LF, LYV, MDR, MED, MM, MMLP, MR, MYGN, NRP, PAA, PDLI, PNG, SBAC, TEG, THQI, TWTC, UAN, VVC, WLT, WTW, XL, Z Comment! [Earnings]
- Sunday, November 4, 2012, 5:35 PM Notable earnings after Monday’s close: ALNY, CF, CLNE, CTRP, CVI, DEPO, ED, ENOC, EOG, ESRX, FIS, FNF, JIVE, LF, LYV, MDR, MED, MM, MMLP, MR, MYGN, NRP, PAA, PDLI, PNG, SBAC, TEG, THQI, TWTC, UAN, VVC, WLT, WTW, XL, Z Comment! [Earnings]
- Tuesday, October 23, 2012, 3:06 PM Isis Pharmaceuticals (ISIS +2%) says it will receive $1.1M from Alnylam Pharmaceuticals (ALNY +0.2%) as its portion of the upfront fees in ALNY's recently announced collaboration with Genzyme. In addition, Isis has the potential to receive royalty payments and a portion of future milestone payments. Already this year, Isis has earned $2.7M from Alnylam as a result of licenses that were supported by Isis' patents. 1 Comment [Healthcare, On the Move]
- Monday, October 22, 2012, 3:59 PM Alnylam Pharmaceuticals (ALNY -1.7%) and Genzyme, a Sanofi (SNY -0.4%) company, team up to develop and commercialize RNAi therapeutics targeting transthyretin for the treatment of transthyretin-mediated amyloidosis in Japan and other Asia-Pacific countries. Comment! [Healthcare]
- Tuesday, September 25, 2012, 7:13 PM Alnylam Pharmaceuticals (ALNY) says the Court has ruled in its favor and denied Tekmira Pharmaceuticals' motion to disqualify ALNY's counsel in an infringement suit ALNY filed in January. The suit is based upon allegations that Tekmira improperly provided lipid nanoparticle-formulated small interfering RNA molecules to pharmaceutical collaborators. In addition, ALNY says it's expanded the infringement action with a suit in Canada. Comment! [Healthcare]
- Tuesday, August 28, 2012, 9:43 AM Monsanto (MON -0.4%) signs a deal with Alnylam Pharmaceuticals (ALNY +3.6%) to use the biopharma's gene-silencing technology to improve its biopesticides. MON gains exclusive rights to use ALNY's platform technology and intellectual property; ALNY will receive $29M in upfront payments plus milestone payments and research funding. Comment! [Commodities, On the Move]
- Wednesday, August 22, 2012, 10:18 AM Alnylam (ALNY -0.7%) announces positive results from a pre-clinical ex vivo study, which takes place outside the organism, that could lead to the development of improved cellular vaccines for cancer and chronic viral infections. Alnylam's focus is RNA interference (RNAi), or the study of how genes are turned on and off in cells. (PR) Comment! [Healthcare]
- Monday, August 6, 2012, 4:16 PM Alnylam Pharmaceuticals (ALNY): Q2 EPS of -$0.25 misses by $0.04. Revenue of $20.9M (+1.5% Y/Y) in-line. Shares -4.7% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Monday, August 6, 2012, 12:10 AM Notable earnings after Monday’s close: ALNY, ALSK, BKD, CBOU, CF, CHK, CLNE, CXO, GA, GEOY, HALO, LEAP, MDR, MR, MTW, NQ, NRP, OAS, PNG, SB, TWTC Comment! [Earnings]
- Sunday, August 5, 2012, 5:35 PM Notable earnings after Monday’s close: ALNY, ALSK, BKD, CBOU, CF, CHK, CLNE, CXO, GA, GEOY, HALO, LEAP, MDR, MR, MTW, NQ, NRP, OAS, PNG, SB, TWTC 3 Comments [Earnings]
- Friday, July 20, 2012, 6:24 AM Alnylam Pharmaceuticals (ALNY) is in discussions with "more than one" potential partner to help it carry out Phase II and Phase III studies of its ALN-PCS treatment for high cholestoral, CEO John Maraganore says, although he declines to name names. Comment! [Healthcare]
- Monday, July 16, 2012, 11:47 AM Alnylam Pharmaceuticals (ALNY) now surging 37% on heavy volume following positive Phase I trial results for ALN-TTR02, a treatment for a genetic mutation of the transthyretin gene. The mutation causes a hereditary, systemic disease called ATTR, which can damage body organs and tissue such as the peripheral nerves and heart. Comment! [On the Move]
- Monday, July 16, 2012, 9:11 AM Alnylam Pharmaceuticals (ALNY) +9.4% premarket after the biotech firm says a study showed ALN-TTR02, a potential treatment for a genetic mutation of the transthyretin gene, reduced serum TTR protein levels in a way that was "rapid, dose dependent, durable, and specific after just a single dose." Comment! [Healthcare, On the Move]
- Thursday, May 3, 2012, 4:52 PM Alnylam Pharma (ALNY): Q1 EPS of -$0.25 beats by $0.10. Revenue of $20.6M (-0.4% Y/Y) beats by $1M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, February 15, 2012, 2:28 PM Off sharply on Tuesday after filing to sell 7M shares, Alnylam Pharmaceuticals (ALNY +14.7%) is more than recouping its losses after pricing its offering (increased to 7.5M shares) at $10.75. A high short interest (11.2% of float shorted as of Jan. 31) could be contributing to recent volatility. Comment! [Healthcare, On the Move]
- Monday, February 13, 2012, 5:06 PM Alnyam Pharmaceuticals (ALNY), which fell after reporting Q4 results last week, is down 4% AH after filing to sell 7M shares, worth $86.7M based on today's close. The company, less than a month removed from announcing a major restructuring plan, says it will use the proceeds to help advance its drug pipeline, including its ALN-TTR02 and ALN-APC drugs. Comment! [Healthcare, On the Move]
-
Michael Kudrna
Biotech: Recent News Updates And Comments: (ALNY) (ATRS) (BPAX) (LGND) (ONXX) (INFI) http://bit.ly/sGjWME - View all 0 replies
-
Michael Kudrna
Biotech: Alnylam (ALNY) Notes From ALN-TTR01 Data Conference Call 11/21/11 http://bit.ly/vgsht6 - View all 0 replies
-
- View all 0 replies
-
Michael Kudrna
Biotech: Alnylam (ALNY) Notes from BioPharm International Podcast http://bit.ly/sIbunA/ - View all 0 replies
-
Justin M. Hall
ALNY, MDT, AEZS, ATRC, ABMD, GERN, => Notable Developments and Results 12/2/10 => Rx Investors.com => http://bit.ly/haFLnm - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES